Jamie brings an extensive background in clinical and preclinical development services, having worked for more than 20 years in clinical and pharmaceutical related business development roles for leading contract development organizations and pharmaceutical services providers.
Jamie will be responsible for account management and territory growth for the company’s global clinical packaging and logistics services in the Pacific Northwest area, maintaining and growing market share with key customers while developing new business as well as identifying opportunities for PCI’s high potency oral solid manufacturing, commercial packaging and analytical testing services.
Commenting on his appointment, Tim Roberts, PCI North America Business Development Director, stated: “We are delighted to welcome Jamie to our team. He brings a great deal of experience and a proven track record in supporting clients across the clinical and pharmaceutical sector. His background will be invaluable in helping our clients in this exciting geographic region of emerging pharmaceutical and biotech companies, helping them realize success in bringing new therapies to market.”
Jamie stated: “I’m excited to join PCI and I am looking forward to applying my previous experience to my new role. I have a long history of working in the industry and fostering strong long-term client relationships. I look forward to leveraging my experience at PCI to deliver the industry’s leading experience to both new and current clients.”
PCI has announced considerable investment in its clinical trials business over the past year, including the expansion of its Cold Chain infrastructure at its North American clinical logistics facility in Rockford, IL, adding cryogenic storage to complement its extensive refrigerated and frozen on-site storage. In addition, the company announced a significant site expansion of its Bridgend, Wales, UK clinical center of excellence. PCI’s Bridgend site also specializes in a broad range of temperature controlled packaging, storage and distribution capabilities including cryogenic storage, complementing the extensive suite of services at the Rockford site.
These developments follow PCI’s announcement of its site expansion for its drug development and clinical trial manufacturing center of excellence in Tredegar, Wales, UK, including the purchase of a fully contained Excelodose 600 unit for contained development of potent compounds in early phase clinical study.
To find out more about PCI, please visit www.pciservices.com.